Delta-Fly Pharma Inc
TSE:4598
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Delta-Fly Pharma Inc
TSE:4598
|
JP |
|
RLJ Lodging Trust
NYSE:RLJ
|
US |
|
B
|
Brg SA
WSE:BER
|
PL |
|
ARYA Sciences Acquisition Corp IV
NASDAQ:ADGM
|
US |
|
Consolidated Lithium Metals Inc
XTSX:CLM
|
CA |
|
P
|
Pushfor Tech Inc
F:713
|
CA |
Delta-Fly Pharma Inc
Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. The company is headquartered in Tokushima-Shi, Tokushima-Ken and currently employs 11 full-time employees. The company went IPO on 2018-10-12. The firm's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. The company is headquartered in Tokushima-Shi, Tokushima-Ken and currently employs 11 full-time employees. The company went IPO on 2018-10-12. The firm's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
